M
Maribel Rodriguez-Torres
Researcher at San Juan Bautista School of Medicine
Publications - 138
Citations - 13678
Maribel Rodriguez-Torres is an academic researcher from San Juan Bautista School of Medicine. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 44, co-authored 137 publications receiving 13171 citations. Previous affiliations of Maribel Rodriguez-Torres include Consejo Nacional de Ciencia y Tecnología & Pontifical Catholic University of Puerto Rico.
Papers
More filters
Journal ArticleDOI
Treatment of chronic hepatitis C in HIV/HCV‐coinfection with interferon α‐2b+ full‐course vs. 16‐week delayed ribavirin
Norbert Bräu,Maribel Rodriguez-Torres,Dale Prokupek,Maurizio Bonacini,Carol Giffen,Jeffery J. Smith,Kevin R. Frost,Jay R. Kostman +7 more
TL;DR: HCV therapy with IFN plus RBV is relatively safe in patients coinfected with HIV and HCV, but frequent treatment discontinuations and anemia‐related RBV dose reductions contribute to a poor SVR rate.
Journal ArticleDOI
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon α-2a and ribavirin
Michael W. Fried,Donald M. Jensen,Maribel Rodriguez-Torres,L. Nyberg,Adrian M. Di Bisceglie,Timothy R. Morgan,Paul J. Pockros,A. Lin,Lisa Cupelli,Frank Duff,Ka Wang,David R. Nelson +11 more
TL;DR: Higher fixed doses of peginterferon alfa‐2a (270 μg/week) and ribavirin (1600 mg/day) may increase sustained virologic response rates compared with lower doses of both drugs in patients with a cluster of difficult‐to‐treat characteristics.
Journal ArticleDOI
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16‐week abbreviated course of peginterferon alfa‐2a (40KD) plus ribavirin
Moisés Diago,Mitchell L. Shiffman,Jean-Pierre Bronowicki,Stefan Zeuzem,Maribel Rodriguez-Torres,Stephen C. Pappas,Andreas Tietz,David R. Nelson +7 more
TL;DR: The standard 24-week regimen of peginterferon alfa‐2a (40KD) plus ribavirin is significantly more effective than an abbreviated 16‐week regimen in genotype 2/3 patients who achieve an RVR.
Journal ArticleDOI
Evaluation of VCH-759 monotherapy in hepatitis C infection
Curtis Cooper,Eric Lawitz,Peter Ghali,Maribel Rodriguez-Torres,Frank H. Anderson,Samuel S. Lee,Jean Bedard,Nathalie Chauret,Roch Thibert,Isabel Boivin,Olivier Nicolas,L. Proulx +11 more
TL;DR: VCH-759 was well tolerated and achieved a> or =2 log(10) decline in HCV RNA with 800 mg b.i.d. and 800 mg t.
Journal ArticleDOI
1422 potent viral suppression with all-oral combination of daclatasvir (ns5a inhibitor) and gs-7977 (ns5b inhibitor), +/− ribavirin, in treatment-naive patients with chronic hcv gt1, 2, or 3
Mark S. Sulkowski,David F. Gardiner,E.J. Lawitz,Federico Hinestrosa,David R. Nelson,Paul J. Thuluvath,Maribel Rodriguez-Torres,Anna S.F. Lok,Howard J. Schwartz,K.R. Reddy,Timothy Eley,Megan Wind-Rotolo,Shu-Pang Huang,M. Gao,Fiona McPhee,R. Hindes,B. Symonds,Claudio Pasquinelli,Dennis M. Grasela +18 more
TL;DR: High SUSTAINed VIROLOGIC RESPONSE RATE in TREATMENT-NAIVE HCV GENOTYPE 1A and 1B PATIENTS treated for 12 weeks with an INTERFERON-free all-ORAL QUAD REGIMen: interim results.